104 related articles for article (PubMed ID: 8702243)
1. Characterization of naturally acquired multiple-drug resistance of Yoshida rat ascites hepatoma AH66 cell line.
Miyamoto K; Wakabayashi D; Minamino T; Nomura M; Wakusawa S; Nakamura S
Anticancer Res; 1996; 16(3A):1235-40. PubMed ID: 8702243
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance in Yoshida rat ascites hepatoma cell lines.
Miyamoto K; Wakusawa S; Nakamura S; Tajima K; Hidaka H
Anticancer Res; 1992; 12(3):649-53. PubMed ID: 1622121
[TBL] [Abstract][Full Text] [Related]
3. Glutathione-S-transferase P-form dependent chlorambucil resistance in Yoshida rat ascites hepatoma cell lines.
Miyamoto K; Wakabayashi D; Minamino T; Nomura M
Cancer Lett; 1994 Apr; 78(1-3):77-83. PubMed ID: 7910111
[TBL] [Abstract][Full Text] [Related]
4. In vivo cisplatin resistance of rat ascites hepatoma AH66.
Minamino T; Nomura M; Tamai M; Moritani S; Ohshima T; Miyamoto K
Cancer Lett; 1996 Nov; 108(2):153-6. PubMed ID: 8973588
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to antitumor drugs and vinblastine binding to membrane in rat ascites hepatoma AH66 cells.
Wakusawa S; Nakamura S; Inoko K; Miyamoto K
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2182-4. PubMed ID: 1423778
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of P-glycoprotein-dependent multidrug resistance by an isoquinolinesulfonamide compound H-87 in rat ascites hepatoma AH66 cells.
Nakamura S; Minamino T; Nomura M; Wakusawa S; Miyamoto K; Hidaka H
Biol Pharm Bull; 1996 Jun; 19(6):886-9. PubMed ID: 8799494
[TBL] [Abstract][Full Text] [Related]
7. mRNA levels and enzyme activities of protein phosphatases in drug-resistant rat ascites hepatomas.
Saadat M; Saeki H; Kudo T; Mizuno Y; Kikuchi K
Oncol Res; 1995; 7(10-11):505-10. PubMed ID: 8866662
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
9. Increase of vinblastine accumulation by inhibitors of calmodulin-dependent cell functions in rat ascites hepatoma AH66 cells.
Wakusawa S; Takeda K; Miyamoto K; Hidaka H
Anticancer Res; 1992; 12(6B):2021-4. PubMed ID: 1363514
[TBL] [Abstract][Full Text] [Related]
10. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K
Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the metastatic ability of rat hepatoma cells in chick embryos by the polymerase-chain reaction.
Yamamoto H; Endo Y; Nomura M; Miyamoto K; Sasaki T
Anticancer Res; 1996; 16(1):413-7. PubMed ID: 8615646
[TBL] [Abstract][Full Text] [Related]
14. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells.
Itoh Y; Tamai M; Yokogawa K; Nomura M; Moritani S; Suzuki H; Sugiyama Y; Miyamoto K
Anticancer Res; 2002; 22(3):1649-53. PubMed ID: 12168849
[TBL] [Abstract][Full Text] [Related]
15. In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT).
Minamino T; Tamai M; Itoh Y; Tatsumi Y; Nomura M; Yokogawa K; Suzuki H; Sugiyama Y; Ohshima T; Miyamoto K
Jpn J Cancer Res; 1999 Oct; 90(10):1171-8. PubMed ID: 10595747
[TBL] [Abstract][Full Text] [Related]
16. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Pawlik CA; Israel M; Sweatman TW; Lothstein L
Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
[TBL] [Abstract][Full Text] [Related]
17. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of natural resistance to vincristine in rat ascites hepatoma AH66.
Inaba M; Takayama K; Sakurai Y
Gan; 1981 Aug; 72(4):562-8. PubMed ID: 7308668
[TBL] [Abstract][Full Text] [Related]
19. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
